Abstract
This study aimed to explore the evaluation of Adriamycin-loaded microspheres in the treatment of liver cancer under DenseNet-based magnetic resonance imaging (MRI) image classification algorithm. According to different treatment methods, the research objects were classified into a normal saline (saline) group, a doxorubicin raw material (DOX) group, and a chitosan cross-linked pectin-doxorubicin conjugate macromolecular (CS-PDC-M) group. DenseNet’s migration learning was employed to analyze the dynamic enhanced MRI characteristics and classify the MRI images. The CS-PDC-M-targeted nanotransfer system was examined with its apparent morphology, drug absorption, and cytotoxicity. Tumor volume was monitored using MRI, and alanine aminotransferase (ALT) and creatine kinase isoenzyme (CK-MB) values were detected. Results showed that the classification accuracy of liver cancer MRI image based on DenseNet model reached 80% at the arterial hepatobiliary stage. The DOX and CS-PDC-M group had obviously smaller tumor volume than that of the saline group P < 0.05 with a statistical meaning. The mortality in the DOX group was 30%, while there was no death in the saline and CS-PDC-M groups. Compared with the saline and CS-PDC-M groups, ALT and CK-MB from the DOX group increased substantially P < 0.05 . Therefore, DOX had an inhibitory effect on tumor but damaged the heart and liver. DOX was used to construct CS-PDC-M that could maintain the original treatment effect of DOX and inhibit its side effects on the body, so CS-PDC-M had a clinical application value. In conclusion, Adriamycin-loaded microspheres could not only maintain the original therapeutic effect of Adriamycin but also inhibit its toxic and side effects on the body. The DenseNet model was applied in the liver cancer MRI dynamic image classification algorithm, and the normalization algorithm could improve the accuracy of the liver cancer microvessel classification, thus promoting the diagnostic efficiency of liver cancer diagnosis, which had clinical application value.
Highlights
Cancer is a disease that seriously harms human health in today’s society, and there are 14 million new cancer patients (782,000 new liver cancer patients) and about 8.2 million deaths (745,000 deaths with liver cancer) worldwide each year [1]. erefore, high mortality makes wary of scientists in the treatment of cancer research
Detection of CS-PDC-M. e surface characteristics of CS-PDC-M were observed by scanning electron microscope (SEM), as shown in Figure 3. e CS-PDC-M presented irregular dispersion state with a diameter of about 200 nm, which met the quality standards of nano-microspheres
Detection Results of the Drug-Loading Capacity and Encapsulation Rate of CS-PDC-M. e amount of free doxorubicin raw material (DOX) was determined by UV, so as to calculate the drug-loading capacity and encapsulation rate of three batches of CS-PDCM. e results of drug-loading capacity are shown in Tables 1 and 2, which indicated the results of encapsulation rate
Summary
Cancer is a disease that seriously harms human health in today’s society, and there are 14 million new cancer patients (782,000 new liver cancer patients) and about 8.2 million deaths (745,000 deaths with liver cancer) worldwide each year [1]. erefore, high mortality makes wary of scientists in the treatment of cancer research. Interventional therapy is the main method of terminal-stage cancer treatment [2] and improves the tumor local drug concentration. What is more, it couples with slowrelease and controlled-release effects to increase the drug effect time, so as to play the efficacy of chemotherapy drugs to an extreme. The cancer treatment research has become a hot topic due to the rise of molecular biology and the emergence of new theory, technology, and knowledge. Drug-loaded microsphere is a new embolism material, and microsphere technology has long-term slow-release or targeted effect
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
